Loading...
MTAA
PHN
Market cap614mUSD
Dec 05, Last price  
54.70EUR
1D
-2.67%
1Q
17.89%
IPO
294.95%
Name

Pharmanutra SpA

Chart & Performance

D1W1MN
MTAA:PHN chart
P/E
31.76
P/S
4.52
EPS
1.72
Div Yield, %
1.55%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
16.76%
Revenues
117m
+15.59%
26,254,66432,998,46937,784,56446,672,50353,811,00058,480,00068,578,00083,394,000101,034,000116,788,000
Net income
17m
+29.43%
2,571,9333,850,8386,030,4898,557,4978,454,00014,072,00013,771,00015,048,00012,832,00016,609,000
CFO
21m
+69.54%
05,861,3865,706,2876,436,10011,983,00011,791,00020,413,00014,466,00012,092,00020,501,000
Dividend
May 06, 20240.85 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
IPO date
Jul 18, 2017
Employees
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT